Crizotinib | Tocris Bioscience 4368/10 product information

product summary

company name :

Tocris Bioscience

product type :

chemical

product name :

Crizotinib

catalog :

4368/10

quantity :

10 mg (also 50 mg)

price :

353 USD

more info or order :

Tocris Bioscience product webpage

citations: 12

Reference
Hadova K, Mesarosova L, Králová E, Doka G, Krenek P, Klimas J. The tyrosine kinase inhibitor crizotinib influences blood glucose and mRNA expression of GLUT4 and PPARs in the heart of rats with experimental diabetes. Can J Physiol Pharmacol. 2021;99:635-643 pubmed publisher
Khan T, Seddon A, Dalgleish A, Khelwatty S, Ioannou N, Mudan S, et al. Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancr. Oncol Rep. 2020;44:2581-2594 pubmed publisher
Maru Y, Tanaka N, Ebisawa K, Odaka A, Sugiyama T, Itami M, et al. Establishment and characterization of patient-derived organoids from a young patient with cervical clear cell carcinoma. Cancer Sci. 2019;110:2992-3005 pubmed publisher
Giménez Xavier P, Pros E, Aza A, Moran S, Tonda R, Esteve Codina A, et al. Deep analysis of acquired resistance to FGFR1 inhibitor identifies MET and AKT activation and an expansion of AKT1 mutant cells. Oncotarget. 2018;9:31549-31558 pubmed publisher
Ayoub N, Al Shami K, Alqudah M, Mhaidat N. Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents. Onco Targets Ther. 2017;10:4869-4883 pubmed publisher
Stanley A, Ashrafi G, Seddon A, Modjtahedi H. Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines. Sci Rep. 2017;7:3964 pubmed publisher
Giménez Xavier P, Pros E, Bonastre E, Moran S, Aza A, Grana O, et al. Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells. Mol Cancer Ther. 2017;16:1366-1376 pubmed publisher
Zhu L, Cheng X, Shi J, Jiacheng L, Chen G, Jin H, et al. Crosstalk between bone marrow-derived myofibroblasts and gastric cancer cells regulates cancer stemness and promotes tumorigenesis. Oncogene. 2016;35:5388-5399 pubmed publisher
Khelwatty S, Essapen S, Seddon A, Fan Z, Modjtahedi H. Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers. Br J Cancer. 2015;113:1010-9 pubmed publisher
Tervonen T, BelitÅ¡kin D, Pant S, Englund J, Marques E, Ala Hongisto H, et al. Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion. Oncogene. 2016;35:1832-46 pubmed publisher
Sullivan K, Padilla Just N, Henry R, Porter C, Kim J, Tentler J, et al. ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. Nat Chem Biol. 2012;8:646-54 pubmed publisher
Qi J, MCTIGUE M, Rogers A, Lifshits E, Christensen J, JÃ¤nne P, et al. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res. 2011;71:1081-91 pubmed publisher

product information

brand :

Tocris

catalog number base :

4368

SKU :

4368/10

product name :

Crizotinib

units size :

10 mg (also 50 mg)

description :

Potent c-MET/ALK inhibitor

target :

MET Inhibitors

category :

Small Molecules

purity :

98%

observed molecular weight :

450.34

url print :

?utm_source=biocompare&utm_medium=referral&utm_campaign=product&utm_term=smallmolecules

details of functionality :

Crizotinib is a potent inhibitor of c-MET and anaplastic lymphoma kinase (ALK) (cell IC50 values are 8.0 and 20 nM respectively). Selective for c-MET and ALK against 120 different kinases. Displays antitumor efficacy in multiple tumor models; inhibits c-MET-dependent proliferation, migration and invasion of human tumor cells in vitro . Orally bioavailable.

top caption :

Potent c-MET/ALK inhibitor

extended description :

Potent c-MET/ALK inhibitor

chemical name text :

3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine

formula :

C21H22Cl2FN5O

formula text :

C21H22Cl2FN5O

cas num :

877399-52-5

USD :

353 USD

product details :

Potent c-MET/ALK inhibitor

alt names :

PF 02341066,PF 2341066

storage :

Store at +4Â°C

more info or order :

Tocris Bioscience product webpage